Valuation: Corcept Therapeutics Incorporated

Market Cap 11.98B 10.38B 9.81B 8.88B 16.67B 1,149B 16.8B 117B 45.05B 583B 45B 44B 1,858B P/E 2026 *
53.8x
P/E 2027 * 25.8x
Enterprise Value 11.98B 10.38B 9.81B 8.88B 16.67B 1,149B 16.8B 117B 45.05B 583B 45B 44B 1,858B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 7.03x
Free-Float
65.9%
Yield 2026 *
-
Yield 2027 * -
1 day-0.88%
1 week-2.77%
Current month-2.23%
1 month-3.19%
3 months+33.33%
6 months+244.70%
Current year+218.45%
1 week 109.3
Extreme 109.3
117.84
1 month 108.25
Extreme 108.25
126.38
Current year 28.66
Extreme 28.6601
126.38
1 year 28.66
Extreme 28.6601
126.38
3 years 20.84
Extreme 20.84
126.38
5 years 15.82
Extreme 15.825
126.38
10 years 5.77
Extreme 5.77
126.38
Manager TitleAgeSince
Chief Executive Officer 68 1998-12-31
Director of Finance/CFO 49 2021-02-28
Chief Tech/Sci/R&D Officer 48 2024-01-31
Director TitleAgeSince
Director/Board Member 68 1998-12-31
Chairman 82 1998-12-31
Director/Board Member 71 2004-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Tax

Chief Financial Officer

-102 0.0001%
9/2/26 Tax

Executive/Senior Manager

-117 0.0001%
9/2/26 Tax

Company Secretary

-91 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%-2.77%+59.38%+231.10% 11.98B
-0.19%+1.09%+51.85%+97.36% 1,013B
+0.33%-0.71%+50.62%+65.50% 644B
+0.49%+5.73%+20.88%+72.92% 465B
+0.54%+4.34%+40.40%+40.65% 352B
+1.01%+3.19%+18.93%+25.21% 264B
+0.82%+4.79%+7.60%+13.80% 253B
-1.53%-4.46%+36.90%+44.08% 203B
+0.59%-3.55%-22.40%-57.16% 188B
-0.08%-0.23%+30.00%+93.34% 181B
Average +0.27%-1.25%+29.42%+62.68% 357.57B
Weighted average by Cap. +0.28%+0.00%+35.06%+60.69%

Financials

2026 *2027 *
Net sales 1.15B 993M 939M 850M 1.6B 110B 1.61B 11.2B 4.31B 55.75B 4.31B 4.21B 178B 1.7B 1.48B 1.4B 1.26B 2.37B 164B 2.39B 16.66B 6.41B 82.92B 6.4B 6.26B 264B
Net income 242M 209M 198M 179M 336M 23.17B 339M 2.36B 908M 11.75B 907M 887M 37.47B 594M 514M 486M 440M 826M 56.94B 832M 5.8B 2.23B 28.87B 2.23B 2.18B 92.08B
Net Debt - -
Logo Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
Employees
730
Date Price Change Volume
26-09-15 US$110.82 -0.88% 1,458,661
26-09-14 US$111.80 -0.88% 1,230,701
26-09-11 US$112.79 -1.85% 1,282,453
26-09-10 US$114.92 -0.67% 683,007
26-09-09 US$115.70 +1.51% 572,048
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
110.82USD
Average target price
141.00USD
Spread / Average Target
+27.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CORT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!